Philippe Agapé

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 405 citations · Full text

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget et al. · Blood · 2016 · 318 citations · Full text

Management and outcome of primary CNS lymphoma in the modern era

Caroline Houillier, Carole Soussain, Hervé Ghesquières et al. · Neurology · 2020 · 229 citations · Full text

High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

Lionel Mannone, Claude Gardin, M.C. Quarré et al. · British Journal of Haematology · 2006 · 100 citations

Hematological Malignancy, Thrombosis, High‐dose Darbepoetin Alpha +15

A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients

Olivier Fitoussi, Virginie Perreau, JM Boiron et al. · Bone Marrow Transplantation · 2001 · 88 citations

Hematological Malignancy, Oncology, Medicine +12